Skip to main content
Compass Pathways: home
  • About us
        • About us

          Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.

        • About us
          • Our purpose
          • Our stories
          • Our values
          • Our approach
        • Our team
          • Executive Team
          • Board of Directors
        • Our stories

          Everyone has a story about how mental health has affected them or someone they know. Our people bring their stories, and a wide range of backgrounds and skills, to Compass.

          Read our stories
  • Our work
        • Our work

          We want to give people living with mental health challenges better options.

        • About psilocybin therapy
        • Pipeline
          • Treatment-resistant depression (TRD)
          • Post-traumatic stress disorder (PTSD)
          • Anorexia nervosa
          • Pipeline overview
          • Investigator-initiated studies
        • Therapist training
        • Preclinical research
          • Discovery Center
        • Digital technologies
          • Digital technology blog
        • Our publications and results
          • COMP360 psilocybin in healthy participants
          • COMP360 psilocybin treatment in TRD
          • COMP360 psilocybin treatment in TRD with antidepressants
          • Therapist training: Frontiers in Psychiatry
        • Partnerships and collaborations
          • Centres of Excellence
          • Partnerships
        • Our approach
          • Compassionate use policy
          • Animal welfare
        • phase II clinical trial of psilocybin therapy
        • News and views

          Read our latest news and updates.

          Read more
  • Join us
        • Join us

          We are united by our commitment to improving mental health.

        • Join us
          • Working at Compass
          • Careers
          • 60 seconds with ...
        • Our purpose

          Watch our purpose video to find out who we are and what defines us.

          Find out more about our purpose
  • News and views
        • News and views

          Our collective understanding of mental illness is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

        • All news and views
          • Our perspectives
          • Our blog
          • Podcast
          • White Paper
        • Compass news archive
        • Digital technology blog
        • Find out how we use digital tools, including AI, software and mathematics, to better understand mental illness.

          Digital technology blog
  • Investors
        • Investors

          We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.

        • News & events
          • News releases
          • Events
          • Presentations
          • SEC filings & annual reports
          • Our annual review
        • Stock information
          • Stock quote & chart
          • Historical price lookup
          • Analyst Coverage
          • Split history
        • Corporate governance
          • Documents & charters
          • Executive Team
          • Board of directors
          • Committee composition
          • Annual general meeting
        • Investor resources
          • Shareholder privacy notice
          • FAQs
          • Email alerts and RSS feeds
          • IR contact
        • COMP360 psilocybin treatment in TRD

          We have completed the largest randomised, controlled, double-blind psilocybin treatment study ever done.

          Read more about COMP360 psilocybin treatment in TRD
  • Impact
        • Impact

          We are working to create positive impact by developing transformative therapies for those who are not helped by current treatments, by helping to build the mental health ecosystem of the future, and by acting responsibly as an organisation.

        • Impact
          • Transformative therapies
          • Mental health ecosystem
          • Responsible organisation
        • About us

          Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.

          Read more about us
  • LinkedIn
  • Youtube
  • Twitter
  • Accessibility
accessibility options
  • High Contrast
  • Greyscale
  • Negative Contrast
  • Readable
  • Reset
Contact us

Centres of Excellence

Our mission is to accelerate patient access to evidence-based innovation in mental health.

An important part of this is understanding how potential new therapies can integrate effectively into health systems, and have a positive impact on people’s lives. Our Centres of Excellence help us to do exactly this.

Formed in partnership with leading academic, research and clinical institutions, our Centres of Excellence are hubs that combine scientific rigour and real-world insights to deliver world-class research and innovation that will help to shape new  models of mental health care.

The Centre for Mental Health Research and Innovation in London, UK

In 2022 we formed a long-term strategic partnership with South London and Maudsley NHS Foundation Trust, the largest mental health trust in the UK National Health Service (NHS), and the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, to accelerate psychedelic research and develop new models of care in the UK. The Centre for Mental Health Research and Innovation officially opened in November 2023.  

Video title

The Centre will be a trial site for cutting edge research studies for serious mental health disorders, including our global phase 3 programme in treatment-resistant depression. It is accelerating research into emerging psychedelic therapies, supporting therapist training, evaluating real-world evidence, and enabling research into digital technologies that may enable personalised, predictive and preventative care models. 

The Centre is located at Maudsley Hospital, London. It is a dedicated and purpose-built space for late-stage clinical trials, and is co-directed by leading clinical investigators, Professor Allan Young and Dr James Rucker.  

Read more

Sheppard Pratt

Centre of Excellence in Baltimore, US

Our Centre of Excellence in Baltimore, launched in January 2021 in partnership with Sheppard Pratt, is modelling the “clinic of the future”, showcasing the best thinking in science, therapy, technology and design. Working as a research facility and innovation lab, it is generating evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience.

View website

Collaboration is key to developing a new approach to mental health, and this is why we are bringing together health innovators for the benefit of patients.

Partnerships
  1. Home
  2. Our work
  3. Centres of Excellence
This website is hosted Green - checked by thegreenwebfoundation.org

This website is powered by renewable energy

Useful links
  • Contact us
  • About psilocybin therapy
  • About us
  • Join us
  • News and views
Follow us
  • LinkedIn
  • Youtube
  • Twitter

Sign up to receive the latest Compass news.

Subscribe
  • Unsolicited Information Policy
  • Terms
  • Privacy
  • myPathfinder privacy

Compass © 2023. All rights reserved. Made by GIG.

The press releases and articles contained in this section are provided for historical purposes only. The information contained in each press release and article is accurate only as of the date each press release and article was originally issued. Compass disavows any obligation to update the information contained in such press releases and articles after the date of their issuance.

You are now leaving Compass Pathways’ website.

Compass does not control and is not responsible for the content on the website you are about to visit. Compass is providing this link as a convenience, and this link does not imply Compass endorsement of any material on the website you are about to visit. Do you wish to continue?